The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?

Figure 2

Putative cytoprotective effects of dipeptidyl peptidase-4 inhibitors on organs/tissues targeted by diabetes, including the heart, vessels, kidney, and retina, that are associated with serious diabetic complications.